Skip to content

Relationship Between ADRB2 Genetic Polymorphisms and the Risk of COPD and T2DM Comorbidity

Relationship Between ADRB2 Genetic Polymorphisms and the Risk of COPD and T2DM Comorbidity

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026546
Enrollment
Unknown
Registered
2019-10-13
Start date
2019-10-15
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

COPD and T2DM comorbidity group:N/A
Healthy control group:N/A

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Control group: (1) aged >40 years; (2) healthy subjects without COPD or T2DM. 2. Test group: COPD group: (1) aged >40 years; (2) patient are diagnosed with COPD according to the 2019 GOLD guide: patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease, spirometry shows the presence of a post-bronchodilator FEV1/FVC 40 years; (2)patient with typical symptoms ,such as polydipsia, polyuria and unexplained weight loss, and any point of blood glucose > =11.1mmol/L, or blood glucose at fasting state >=7.0mmol/L or blood glucose >=11.1mmol/L 2 hours after 75g glucose load; (3)exclude patients with COPD. COPD and T2DM group: (1) aged >40 years; (2)patients with COPD and T2DM.

Exclusion criteria

Exclusion criteria: 1. History of asthma or other respiratory diseases (bronchodilation, interstitial pneumonia, occupational lung disease, sarcoidosis, etc.); 2. History of lobectomy or lung cancer; 3. Tuberculosis: active tuberculosis, old tuberculosis affects lung function (such as chronic fibrovascular tuberculosis, lung damage, tuberculous pleurisy caused by extensive pleural hypertrophy); 4. Clinically significant history of circulatory failure; 5. Obvious contraindications for spirometry (history of myocardial infarction, cerebral artery or aortic aneurysm, history of eye surgery, hemoptysis).

Design outcomes

Primary

MeasureTime frame
ADRB2;spirometry;HbA1c;blood glucose;

Countries

China

Contacts

Public ContactShujuan Jiang

Shandong Provincial Hospital

docjiangshujuan@163.com+86 15168887199

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026